Lymphoma

- **Lymphoma, NOS**
- **Hodgkin lymphoma**
- **Non-Hodgkin lymphoma**
  - **B-cell lymphomas**
  - **T-cell lymphomas**
  - **Various non-hodgkin lymphomas**

**Lymphoma, NOS**

- **10002**: A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas
- **10106**: A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas
- **10014**: A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
- **10145**: Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas
- **10299**: A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

**Non-Hodgkin lymphoma**

- **10244**: Phase I Study of GSK525762 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas

**B-cell lymphomas**

- **9875**: Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
- **9924**: A Phase I Trial of the Combination of Lenalidomide and Binatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
- **10089**: A Randomized Phase 2 Study of CDX-1127 (Varilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
- **10193**: Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

**T-cell lymphomas**

- **10130**: A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors or B-Cell Lymphomas with Hepatic Dysfunction

**Various non-hodgkin lymphomas**

- **9930**: A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

**Hodgkin lymphoma**

- **10204**: Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

**Expansion**: Diffuse large B-cell lymphoma (including high-grade B-cell lymphoma and transformed diffuse large B cell lymphoma)

**Expansion**: At least one pancreatic cancer cohort and possibly others.